2 New Arbaclofen Studies Getting Lots of Press!

Two complementary studies were just published in Science Translational Medicine, and they’ve been getting a ton of attention in the media. Since lots of people are asking about these articles, and reporters have been calling to get my comments (and occasionally misquoting me), I thought I’d give my official commentary here. The first article (Henderson ...

New Sites recruiting for the Seaside Therapeutics Fragile X Clinical Trial of arbaclofen

Seaside Therapeutics has added new sites in Houston and San Diego for their trial of arbaclofen (STX209).  More information at http://www.harbortrial.com/about-the-Clinical-trial including this great map of their trial sites: list of sites recruiting for this and other trials: http://fraxa.org/joinstudies.aspx

Boston Children’s Hospital is now accepting ages 12-18 for trial of AFQ056 from Novartis

Here’s the complete list of sites recruiting for this and other trials: http://fraxa.org/joinstudies.aspx

Investigational New Drugs in Clinical Trials for Fragile X: What do they Do?

From the FRAXA Clinical Trials webinar … Dr. Mike Tranfaglia explaining the scientific background behind mGluR5 antagonists and arbaclofen.

FRAXA Clinical Trials webinar slides and Q&A

FRAXA Clinical Trials webinar slides and Q&A
If you weren’t able to catch our webinar we’re posting it here in sections. More about the trials and clinic locations and contacts slides from the webinar (pdf) Please comment below to ask your questions. Question: How do families decide which trial is best for them? Answer: Each of the trials has different requirements for ...

Fragile X syndrome reversed in adult mice

Neuron just published a new study showing that a compound that inhibits mGluR5 to correct signs of Fragile X. The work was done by a team led by Dr. Lothar Lindemann at Roche, and a group led by Dr. Mark Bear at MIT. I’ve just finished reading the new article, and I must say it ...

Clinical trials for Fragile X children and adults

It’s taken many years to get to this point, but here we are with multiple treatment trials in progress.  Every few days I talk with someone who is either participating in one of the trials or thinking about doing so.  I wonder if we’ll soon come to a point when most families – no matter ...